Table 6 Ongoing Clinical Trial of Liquid Biopsy for T-cell Lymphoma
From: Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application
NCT/ChiCTR Number | Biomarker | Liquid Biopsy | Disease | Study Title |
|---|---|---|---|---|
NCT03829540 | cytokine | serum | T-cell Lymphoma|T-cell Leukemia | CD4CAR for CD4 + Leukemia and Lymphoma |
NCT03789617 | cytokine | plasma | EBV Associated Extranodal NK/T-cell Lymphoma|EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma | A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8 + T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive |
NCT05398614 | cytokine | peripheral blood | T-ALL|Lymphoma | SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7 + Hematolymphoid Malignancies |
NCT04848064 | cytokine | peripheral blood | Adult T-Cell Leukemia/Lymphoma/ Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma |
NCT04676789 | EBV-DNA | peripheral blood | Extranodal NK/T-cell Lymphoma, Nasal Type | Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL |
NCT05833893 | ctDNA and EBV copy number | peripheral blood | NK/T-cell Lymphoma|Newly Diagnosed|Advanced Lymphoma | Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma |
NCT05885464 | MRD | peripheral blood | /Lymphoma|Lymphoblastic Leukemia | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) |
NCT05745714 | MRD | peripheral blood | Acute Lymphoblastic Leukemia | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies |
NCT05740449 | MRD | peripheral blood | Acute Lymphoblastic Leukemia | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies |
NCT05658640 | MRD | peripheral blood | Acute Lymphoblastic Leukemia | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies |
NCT05626400 | MRD | peripheral blood | T-cell Acute Lymphoblastic Leukemia/Lymphoma | Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7 + Acute T-ALL/T-LBL |
NCT05618041 | MRD | peripheral blood | Acute Lymphoblastic Leukemia|Lymphoma|Multiple Myeloma | The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies |
NCT05212584 | MRD | peripheral blood | Relapsed/Refractory, High Risk Hematologic Malignancies|T-ALL/Lymphoma | CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7 + T -Acute Lymphoblastic Leukemia/ Lymphoma |
NCT05043571 | MRD(Ig/TCR) | peripheral blood | Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Leukemia|Lymphoblastic Leukemia | CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia |
NCT04315324 | MRD | peripheral blood | Recurrent T Acute Lymphoblastic Leukemia|Refractory T Acute Lymphoblastic Leukemia | Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) |
NCT03297697 | MRD(Ig/TCR) | peripheral blood | Peripheral T Cell Lymphoma | Minimal Residual Disease in Peripheral T-cell Lymphoma |
NCT03117751 | MRD | bone marrow, blood, and cerebrospinal fluid | Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma |
NCT02737046 | MRD(TCR) | peripheral blood | Adult T-cell Leukemia-Lymphoma|ATLL | Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma |
NCT04480125 | cfDNA | peripheral blood | Peripheral T-cell Lymphoma | Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy |
NCT04480099 | cfDNA | peripheral blood | Peripheral T-cell Lymphoma | Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma |
ChiCTR2200060450 | ctDNA | peripheral blood | Peripheral T-cell lymphoma (PTCL) | Dynamic monitoring of peripheral T-cell lymphoma (PTCL) patients in China based on circulating tumor DNA |
NCT05230680 | MRD | peripheral blood | T Cell Lymphoma | Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) |
NCT05149170 | MRD | peripheral blood | Early-stage|Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type | Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL |
NCT04423536 | SNP Signature | Liquid Biopsy | Natural Killer T-cell Lymphoma | Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell Lymphoma |
NCT04881838 | NPM-ALK or ALK-variants level | peripheral blood or bone marrow | Pediatric Anaplastic Large Cell Lymphoma | CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL |
NCT04904146 | Epigenetic changes | peripheral blood | Mycosis Fungoides|Sezary Syndrome | Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Szary Syndrome |
NCT05157581 | MRD | peripheral blood | Sezary Syndrome | Extracorporeal Photopheresis in Sezary Syndrome |
NCT04582487 | genomic, DSRP, phosphoproteomic | bone marrow and/or peripheral blood | T Acute Lymphoblastic Leukemia|Early T Acute Lymphoblastic Leukemia|T-lymphoblastic Lymphoma|Etp All | Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL |
NCT03385226 | mononuclear cell phenotyping, T cell clones, tumour infiltrating lymphocyte specific neo-antigens | peripheral blood | Cutaneous T Cell Lymphoma|Mycosis Fungoides/Sezary Syndrome | A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) |
NCT04676087 | Cytokines,T cell populations( T-regulatory cells and CD8 + cytotoxic T-cells),Changes in genomic profiles | peripheral blood | Mycosis Fungoides|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides |